TxCell Strengthens its Board of Directors
News Apr 17, 2015
TxCell SA has announced that it has appointed Dr. David Solomon as an additional independent member of the board and Chair of the Remuneration and Nominations sub-committee of the board.
Dr. David Solomon has extensive experience as a CEO in a number of listed biotech companies as well as other companies involved in healthcare investing and pharmacology research. Dr. Solomon is currently the President and CEO of Bionor, a NASDAQ OMX Oslo listed therapeutic vaccine company based in Oslo, Norway, with other offices in Copenhagen, Denmark, and New York, US.
“TxCell is delighted to further strengthen the board with the appointment of Dr. David Solomon. David will add to TxCell a considerable depth of experience across the biotech and healthcare investing sectors gained in both Europe and the US,” said François Meyer, Executive Chairman, TxCell. “TxCell’s development of Ovasave®, its lead personalized T-cell immunotherapy in refractory Crohn’s disease and Col-Treg, its second product candidate from the ASTrIA product platform for the treatment of autoimmune uveitis, benefits from a board with an enviable set of specialist skills, experience and expertise.”
Prior to joining Bionor, Dr. Solomon was CEO of Zealand Pharma A/S from 2008 to 2015. From 2003 to 2006 he headed healthcare investing at Carrot Capital Healthcare Ventures in New York, US. Dr. Solomon has held several leadership positions at a number of biotechnology, pharmaceutical and medical device companies, including Remedy Pharmaceuticals, Critical Diagnostics and Vital Sensors. In addition, he is currently on the boards of Onxeo in Paris (Euronext and NASDAQ OMX) and Promosome, in La Jolla, CA, US.
Dr. Solomon studied medicine and immunology at Cornell Medical College and the Sloan Kettering Cancer Center in New York where he received his doctorate in 1991. Dr. Solomon has served as a faculty member at Columbia University’s College of Physicians and Surgeons.
“TxCell’s innovative personalized T-cell immunotherapies are at the forefront of one of the most exciting new areas in medicine. TxCell’s approach has the potential to create life-changing therapies for patients suffering from a range of severe chronic and refractory autoimmune inflammatory diseases,” said David Solomon. “I am delighted to join the Board of TxCell and to be able to bring my experience to support the development of TxCell and its potentially life-changing therapies.”
Macrophage's Role in Maintaining Tattoos Could Hold Key to RemovalNews
Researchers have discovered that, though a tattoo may be forever, the skin cells that carry the tattoo pigment are not. Instead, the cells can pass on the pigment to new cells when they die. The study suggests ways to improve the ability of laser surgery to remove unwanted tattoos.READ MORE
New Causes of Cellular Decline in Prematurely Aging Kids DiscoveredNews
In a recent paper published in Cell Reports, Saint Louis University researchers have uncovered new answers about why cells rapidly age in children with a rare and fatal disease. The data points to cellular replication stress and a mistaken innate immune response as culprits, and the team found success in the laboratory in blocking these processes with vitamin D.READ MORE
Measuring Neutrophil Motility Could Lead to Accurate Sepsis DiagnosisNews
Mass. General researchers design device that rapidly diagnoses sepsis with more than 95 percent accuracy.READ MORE
Comments | 0 ADD COMMENT
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018